Related Experiment Video

Updated: Oct 17, 2026

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
09:01

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

Cyclooxygenase-2, a colorectal cancer nonsteroidal anti-inflammatory drug target, is regulated by c-MYB

R G Ramsay1, A Friend, Y Vizantios

  • 1Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia. r.ramsay@pmci.unimelb.edu.au

Cancer Research
|April 15, 2000
PubMed

Insights

The transcription factor c-MYB activates Cyclooxygenase-2 (COX-2) in colorectal cancer (CRC). This discovery offers a new therapeutic target for CRC management by understanding COX-2 overexpression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Cyclooxygenase-2 (COX-2) is a key target for colorectal cancer (CRC) prevention and treatment.
  • The precise mechanism driving COX-2 overexpression in CRC remains unclear.
  • High levels of transcription factor c-MYB correlate with COX-2 levels in CRC.

Purpose of the Study:

  • To investigate the role of c-MYB as a potential activator of COX-2 transcription in colorectal cancer.
  • To identify and characterize c-MYB binding sites within the human COX-2 promoter region.

Main Methods:

  • Bioinformatic analysis to identify potential c-MYB binding sites in the COX-2 promoter.
  • Reporter gene assays to assess the transcriptional activity of the COX-2 promoter regulated by c-MYB.
  • Use of dominant-negative Myb to evaluate the effect on COX-2 transcription.

Main Results:

  • Thirteen potential c-MYB binding sites were identified in the human COX-2 promoter.
  • Eight of these sites demonstrated moderate to high-affinity DNA binding for c-MYB.
  • Promoter studies confirmed that c-MYB activates COX-2 transcription, while dominant-negative Myb inhibits it.

Conclusions:

  • This study provides the first mechanistic explanation for COX-2 overexpression in colorectal cancer.
  • c-MYB is identified as a direct activator of COX-2 transcription in CRC.
  • Targeting the c-MYB/COX-2 pathway presents a novel therapeutic strategy for colorectal cancer management.

Related Concept Videos

Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...